US20210290058A1

Movatterモバイル変換

Info

Publication number: US20210290058A1
Application number: US17/189,605
Authority: US
Inventors: Chris Bergstrom; Jay Butterbrodt; Alan W. Fiedler; Barry H. Ginsberg; Tim H. Gordon; Paul Upham
Original assignee: Becton Dickinson and Co
Current assignee: Embecta Corp
Priority date: 2006-03-23
Filing date: 2021-03-02
Publication date: 2021-09-23
Also published as: EP2529783A1; JP2009532768A; EP2529784A1; EP2529783B1; CA2646279C; US8285487B2; WO2007112034A2; EP1998840A2; EP1998840A4; WO2007112034A3; US10966608B2; US9848774B2; JP2012210441A; US20180146854A1; EP2529784B1; ES2741178T3; US20130030841A1; CA2883977A1; CA2646279A1; ES2736954T3

Abstract

Methods, devices and a system for disease management are provided that employ diagnostic testing devices (e.g., blood glucose meters) and medication delivery devices (e.g., insulin delivery devices) for providing data to a repository in real-time and automatically. Repository data can be analyzed to determine such information as actual test strip use, patient health parameters outside prescribed ranges, testing and medication delivery compliance, patient profiles or stakeholders to receive promotional items or incentives, and so on. Connected meters and medication delivery devices and repository data analysis are also employed to associate a diagnostic test to a mealtime based on timing of a therapeutic intervention performed by an individual.

Description

This application is a continuation of U.S. patent application Ser. No. 15/850,135, filed Dec. 21, 2017, which is a continuation of U.S. patent application Ser. No. 13/601,163, filed Aug. 31, 2012, now U.S. Pat. No. 9,848,774, which is a divisional application of U.S. patent application Ser. No. 12/293,120, filed Sep. 16, 2008 and having a 35 U.S.C. § 371(c) date of Feb. 23, 2009, now U.S. Pat. No. 8,285,487, which claims the benefit under 35 U.S.C. § 371 of PCT/US2007/007314, filed Mar. 23, 2007, which claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional patent application Ser. No. 60/784,760, filed Mar. 23, 2006; the contents of each being incorporated herein by reference.

BACKGROUND OF THE INVENTIONField of the Invention

The present invention generally relates to improved methods, devices and system for disease management. More particularly, the present invention relates to real-time communication of data between devices (e.g., blood glucose meters, insulin delivery devices) and a repository and analysis of repository data to obtain information to improve disease management and provide cost savings to disease management stakeholders.

Description of the Related Art

FIG. 1 illustrates an existingsystem10 for diabetes management. For convenience, the following abbreviations shall be used herein:

BGM blood glucose meter
DM diabetes management
DMC disease management companies
DMD diabetes management data
WM wireless BGM

As shown inFIG. 1, apatient12 performs blood glucose monitoring (e.g., using lancets and aBGM18 with test strips, or a continuous meter) and administers insulin injections (e.g., via a syringe, pen or pump20) as needed. The BGM and the insulin injections are typically recorded manually in anotebook22 by the patient or his or her caregiver to share with a healthcare provider such as adoctor14 or adisease management company16. This information is typically shared via telephone (e.g.,

telephone

26,28 and32), computer (e.g.,computers24 and30), or in person during office visits. This information can also include information relating to diet, exercise and other factors that influence diabetes management outcomes. Unfortunately, this information is not verified and often not recorded, collected or managed in a reliable and cohesive manner to be useful to the patient's healthcare team in facilitating optimal diabetes management.

With continued reference toFIG. 1, diabetes management data such as blood glucose tests and insulin intake can be recorded using a personal computer (PC)24, as opposed tohandwritten recordkeeping22, or uploaded to a patient'sPC24 from a device (e.g., ablood glucose meter18 or insulin delivery pen20) using a software interface. Conventional communications interfaces, however, are inconvenient because a patient12 must acquire a communication interface such as a specialized modem and/or install software on aPC24 to upload data from aBGM18. Further, such PC interfaces for diabetes data management do not necessarily allow the entered data to be shared with other stakeholders in diabetes management and care, that is, physicians andother healthcare providers14, insurers, or disease management companies (DMCs)16 that are typically hired by employers or insurance companies, as indicated by the optional lines shown in phantom inFIG. 1. If diabetes management data from a patient14 can be provided to a healthcare team member'sPC30, that information is generally not recorded in a comprehensive manner that assures completeness, accuracy and timeliness of the data. For example, quite oftenpatients14 fail to test, or to write down, enter or upload a blood glucose test result or insulin injection, leaving

healthcare team members

30 and16 with incomplete information and not allowing them to identify teachable moments or events in diabetes management or respond in real-time.

Cell phones combined with diabetes data management functions have been proposed, not surprisingly in an era of increasingly indispensable personal electronic devices. For those with chronic conditions such as diabetes, technical convergence of healthcare and personal electronic technology makes even more sense to facilitate use of medications, meters, pumps, injections, and the need to carefully track and document important health data, particularly for those with chronic conditions that require significant self-management.

Several medical companies are developing smarter, more convenient monitoring equipment and are using telecommunications technology to create multipurpose, portable devices for patient use. One of these companies is HealthPia America, a Newark, N.J.-based telemedicine venture that has developed a cell phone that also serves as a blood glucose monitor and features a pedometer. An embedded electronic biosensor in the battery pack enables the cell phone to have a glucose meter function. The sensor reads blood glucose levels from a strip. The data is then uploaded to the cell phone's display. The phone can be programmed to send the information instantly to ahealth care provider14, parent, or guardian. Movement and exercise also can be monitored with the built-in pedometer. The phone can be programmed to send an alert to the caregiver or clinician via short-message service if there is no pedometer reading for a pre-programmed length of time. The care manager can call back to check if thepatient12 is okay, and if there is no response, prearranged emergency procedures can be initiated. This feature could be especially useful for detecting insulin reactions or severe hypoglycemia indiabetes patients12. The biggest advantage of the Diabetes Phone is its alarm features, which allow a physician to set specific parameters. If the phone reports continuously high blood glucose, for example, a doctor can react in real-time.

Other diabetes cell-phone projects include research at Oxford University in the U.K. to test a system similar to that of HealthPia America. In another venture,British patients12 with diabetes have been able to register since 2002 with Sweet Talk, a message service that reminds them via cell phone to take their insulin and offers general education about living with diabetes. Further, in 2003, IBM announced that its “Bluetooth” short-range wireless technology could be used to intercept a person's12 heart rate and send it to a cell phone.

At the ITU Telecom Asia 2004 show in Korea, LG Electronics showed a novel handset, the KP8400. The KP8400 is designed for diabetics and is capable of doing blood sugar level tests just as would a dedicated device.Users12 place a strip of testing paper into the sensor located in the phone's battery pack, place a drop of blood on the end of the strip, and then get a reading from the phone. The reading can then be uploaded to an online database for later retrieval. LG Electronics has a strategic alliance with Healthpia Co., Ltd. to implement the KP8400.

Whether these new and proposed electronic devices for diabetes management will result in their widespread adoption and better self-care forpatients12, or simply more work forclinicians14 as they strive to manage a new stream of information, is the central question as this new frontier of electronic medicine is explored. For example, the data reported by one of these emerging cell phone technologies does not appear to be managed in a cohesive manner such that the real-time test results can be associated with other information such as test trip lot number and use verification, or mealtime events and therapy intervention (e.g., insulin injection), and the like.

Further, what is largely overlooked is the value to less traditional stakeholders in the business of DM. A need therefore exists for business models, methods and apparatuses that maximize the value of collected DMD for various stakeholders such asdisease management companies16, insurers and healthcare networks.

As stated above,disease management companies16 are typically hired by a patient's insurer or employer to provide thepatient12 with educational support for their disease. DMCs obtain claims data such as prescriptions and visits tohealthcare providers14, as well as other data such as BG measurements, insulin dosages, diet and exercise. Much of this information is collected from thepatient12 via telephone (e.g.,

telephones

26,28 and32) which is problematic for a number of reasons. For whatever reasons, patients are often not completely truthful with theirhealthcare providers14 andDMC16 representative about their DM lifestyle choices (e.g., diet, exercise, BG testing and medicating with insulin). Some of the reasons are inadequate education about diabetes self-management, apathy, embarrassment, economic barriers, lack of proficiency in testing and use of data interface equipment, or faulty equipment or testing technique (e.g., poor timing with respect to meal times).

A need therefore exists for a diabetes data management system that allowsDMCs16 and other third parties (e.g., insurance companies, Medicare, Medicaid, HMOs, etc.) to providepatients12 with incentives to take better care of themselves and manage their diabetes and otherwise improve their outcomes. For example, a need exists for a system that can monitor and have verification of a patient's actual blood glucose monitoring practices. ADMC16 can then, for example, remove economic barriers by giving patients, who have shown progress in managing their diabetes, test strips and/or a blood glucose monitor at nominal cost or no charge or by waiving their co-pays.

Currently, reimbursement for diabetes testing supplies by third parties (e.g., insurance companies, Medicare, Medicaid, HMOs, etc.) is based on a model where a specific number of BGM test strips are covered depending on the patient's condition (e.g., aperson12 with diabetes who requires insulin injections to help manage their diabetes may have coverage for 60 BGM test strips per month (2 per day); or aperson12 with diabetes who uses an oral medication to help manage their diabetes may have coverage for 30 BGM test strips per month (1 per day).) In this model, the refill of a BGM test strip prescription is the only indication of use of the BGM test strips. However, this does not provide any objective evidence: a) that the patient12 actually tested their blood glucose using the BGM test strips; b) that the tests were done at appropriate times; c) of the results of any tests that were done. In some situations,patients12 may “stockpile” their test strips or provide them to other family members or friends who do not have equivalent insurance coverage for their needs. In these cases, the third party payor is making payments for testing supplies that are not being used or not being used appropriately. In this model, for example, the mail order supplies company and, ultimately, the BGM test strip manufacturer benefit because they are paid by the third parties for all test strips that are delivered to the patient regardless of the patient's actual use. A need therefore exists for a “pay for results” model wherein a payor pays for only those strips that are actually used.

SUMMARY OF THE INVENTION

Aspects of the exemplary embodiments of the present invention address at least the above problems and/or disadvantages and provide at least the advantages described herein.

For example, an exemplary embodiment of a DM system is provided that simplifies patient involvement with DMD reporting by automating sharing of collected data among other stakeholders. Preferably, there is no patient involvement in the automated data movement (e.g., not even the need to press a “Send” button to upload BG measurement data to a stakeholder, or the more user-intensive option of connecting their BGM device to a computer or other communications device).

An exemplary embodiment of a DM is provided that improves patient compliance for record-keeping and sharing information with healthcare providers. For example, data collected accurately reflects status of patient and obviates failure to test for or reporting of events of interest to stakeholders, use of bad test strips, etc.

Exemplary embodiments of DM system business models are provided that emphasize payors' use of data and not only patients' use of data, and emphasizes the value of the DMD versus the devices used to collect the data.

In accordance with an example embodiment of the present disclosure, a disease management system is provided that comprises: a blood glucose monitoring device configured to detect blood glucose via a blood glucose sensor, and comprising a first communications interface circuit configured to transmit blood glucose data to another device via at least one of a local area network and a near field communication network; the other device comprising a second communications interface circuit configured to receive the blood glucose data from the blood glucose monitoring device and a third communications interface circuit configured to wirelessly connect via at least one of a cellular network and a wireless internet network to a repository that stores disease management information, and to transmit the blood glucose data to the repository; wherein the other device is configured to automatically, without user involvement, transmit the blood glucose data to the repository.

In accordance with an aspect of an example embodiment of the present disclosure, the other device is a cellular telephone, and is configured to automatically, without user involvement, transmit the blood glucose data to the repository in response to detection of cellular telephone activation and selected motion activation of the cellular telephone.

In accordance with an aspect of an example embodiment of the present disclosure, the system further comprises a medication delivery pump configured to control delivery of medication and having a fourth communications interface circuit configured to transmit medication delivery information to the other device via at least one of a local area network and a near field communication network. The medication delivery information is selected from the group consisting of a medication type, medication amount delivered, time stamp for medication delivery.

In accordance with an aspect of an example embodiment of the present disclosure, the other device is a cellular telephone, and is configured to automatically, without user involvement, transmit the medication delivery information to the repository in response to detection of cellular telephone activation and selected motion activation of the cellular telephone.

In accordance with an aspect of an example embodiment of the present disclosure, wherein the medication delivery information relates to insulin doses performed by the pump and the other device configured to automatically, without user involvement, transmit the medication delivery information to the repository in response to detection of an event wherein the blood glucose data is transmitted from the other device to the repository.

In accordance with an aspect of an example embodiment of the present disclosure, the system further comprises a medication delivery pen comprising a medication delivery mechanism, a memory to store medication delivery information relating to operation of the medication delivery mechanism, and a fourth communications interface circuit configured to transmit the medication delivery information to the other device via at least one of a local area network and a near field communication network.

In accordance with an aspect of an example embodiment of the present disclosure, the medication delivery information relates to operation of the medication delivery mechanism to deliver medication and is selected from the group consisting of a medication type, medication amount delivered, time stamp for medication delivery for one or multiple doses.

In accordance with an example embodiment of the present disclosure, a method of disease management is provided that comprises: determining blood glucose data of a patient via a blood glucose sensor; transmitting the blood glucose data from a blood glucose monitoring device to another device via a first communication circuit and a second communications interface circuit configured, respectively, to transmit and receive the blood glucose data via one of a local area network and a near field communication network; wirelessly connecting the other device to a repository of disease management information via a third communications interface circuit in the other device, the third communications interface circuit being configured to wirelessly connect to the repository via at least one of a cellular network and a wireless internet network; and automatically, without user involvement, transmitting the blood glucose data to the repository from the other device.

In accordance with an aspect of an example embodiment of the present disclosure, the other device is a cellular telephone, and the method further comprises automatically, without user involvement, transmitting the blood glucose data from the cellular telephone to the repository in response to detection of cellular telephone activation and selected motion activation of the cellular telephone.

In accordance with an aspect of an example embodiment of the present disclosure, the method further comprises connecting a medication delivery pump to the other device, the medication delivery pump configured to control delivery of medication and having a fourth communications interface circuit configured to connect to the other device via at least one of a local area network and a near field communication network; and transmitting medication delivery information from the medication delivery pump to the other device via the fourth communications interface circuit, the medication delivery information selected from the group consisting of a medication type, medication amount delivered, time stamp for medication delivery.

In accordance with an aspect of an example embodiment of the present disclosure, the other device is a cellular telephone, and the method further comprises automatically, without user involvement, transmitting the medication delivery information to the repository in response to detection of cellular telephone activation and selected motion activation of the cellular telephone.

In accordance with an aspect of an example embodiment of the present disclosure, wherein the medication delivery information relates to insulin doses performed by the pump, and the method further comprises automatically, without user involvement, transmitting the medication delivery information from the other device to the repository in response to detection of an event wherein the blood glucose data is transmitted from the other device to the repository.

In accordance with an aspect of an example embodiment of the present disclosure, the method further comprises: connecting a medication delivery pen to the other device, the medication delivery pen comprising a medication delivery mechanism, a memory to store medication delivery information relating to operation of the medication delivery mechanism, and a fourth communications interface circuit configured to connect to the other device via at least one of a local area network and a near field communication network; and transmitting the medication delivery information to the other device via the fourth communications interface circuit, the medication delivery information relating to operation of the medication delivery mechanism to deliver medication and selected from the group consisting of a medication type, medication amount delivered, time stamp for medication delivery for one or multiple doses.

In accordance with an aspect of an example embodiment of the present disclosure, the medication delivery information relates to insulin doses performed by the medication delivery pen, and the method further comprising automatically, without user involvement, transmitting the medication delivery information from the other device to the repository in response to detection of an event wherein the blood glucose data is transmitted from the other device to the repository.

In accordance with an aspect of an example embodiment of the present disclosure, the other device is a cellular telephone having a display and being programmed to generate a dialog screen to request input of food intake from a patient, and the method further comprises: transmitting from the cellular telephone to the repository diet information related to the food intake input; and analyzing data stored at the repository selected from the group consisting of the blood glucose data, the medication delivery information and the diet information and determining at least one of a calculated insulin dose, and a message for the patient indicating intervention needed based on the blood glucose data.

In accordance with an aspect of an example embodiment of the present disclosure, the method further comprises connecting at least one exercise monitoring device to the cellular telephone or repository, the monitoring device comprising a detector for sensing exercise by the patient, the data stored at the repository further comprising data related to sensed exercise, the cellular telephone being configured to transmit the data related to sensed exercise to the repository; wherein the analyzing the data stored at the repository comprises using the data related to sensed exercise when determining the calculated insulin dose.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects, features, and advantages of certain exemplary embodiments of the present invention will be more apparent from the following detailed description, taken in conjunction with the accompanying drawings in which:

FIG. 1 shows current flow of data and information between patients and their disease management devices and stakeholders;

FIG. 2 shows stakeholders in disease management and the typical flow of information;

FIG. 3 shows wireless connectivity and RF communication pathway options to improve flow of data and information between patients and their disease management devices and stakeholders and a repository in accordance with an exemplary embodiment of the present invention;

FIG. 4 is a block diagram of a repository in accordance with an exemplary embodiment of the present invention;

FIGS. 5A and 5B are perspective views of a wireless meter constructed in accordance with an exemplary embodiment of the present invention;

FIG. 6 is a block diagram of a wireless meter constructed in accordance with an exemplary embodiment of the present invention;

FIG. 7 is a block diagram of a wireless meter employing wireless USB connectivity in accordance with an exemplary embodiment of the present invention;

FIG. 8 is a block diagram of a wireless meter employing WiFi or WiMax connectivity in accordance with an exemplary embodiment of the present invention;

FIG. 9 is a block diagram of a wireless meter employing Bluetooth or ZigBee connectivity in accordance with an exemplary embodiment of the present invention;

FIGS. 10A and 10B are block diagrams of a wireless meter employing a built-in or cell modem attachment for connectivity in accordance with an exemplary embodiment of the present invention;

FIGS. 11A, 11B and 11C are, respectively, a perspective view, a top view and a side view of a base station and meter in accordance with an exemplary embodiment of the present invention;

FIGS. 11D, 11E and 11F are respective views of a base station and meter, that is, a meter-only perspective view, and meter side view showing a port to connect with base station, and block diagram of docking station components and meter components with corresponding interfaces for connection to each other, in accordance with an exemplary embodiment of the present invention;

FIGS. 12A and 12B are block diagrams of a base or docking station and a meter having connectivity to a repository directly or via a device in accordance with an exemplary embodiment of the present invention;

FIGS. 13A, 13B and 13C are perspective side and back views of a BGM in a cell phone in accordance with an exemplary embodiment of the present invention;

FIG. 14 is a block diagram showing connectivity of a BGM in a cell phone in accordance with an exemplary embodiment of the present invention;

FIGS. 15A, 15B, 15C and 15D illustrate a connected syringe in accordance with an exemplary embodiment of the present invention;

FIGS. 16A, 16B, 16C, 16D and 16E illustrate a connected pen in accordance with an exemplary embodiment of the present invention;

FIG. 17 is a block diagram showing connectivity of a pen or syringe in accordance with an exemplary embodiment of the present invention;

FIGS. 18A and 18B illustrate a flow chart for use of test data by a DMC in accordance with an exemplary embodiment of the present invention;

FIG. 19 is a flow chart illustrating use of test data to control test strip refills, promotional items and the like in accordance with an exemplary embodiment of the present invention;

FIG. 20 is a flow chart illustrating use of test data to enroll patients in monthly service connectivity contract and manage incentives disbursements and the like in accordance with an exemplary embodiment of the present invention;

FIGS. 21A and 21B show, respectively, the front and back views of a blood glucose monitor containing a radio frequency identification transponder in accordance with an exemplary embodiment of the present invention;

FIG. 22 shows a blood glucose test strip container with a radio frequency identification transponder integrated into the outside label in accordance with an exemplary embodiment of the present invention;

FIG. 23 shows a blood glucose test strip container with a radio frequency identification transponder integrated into the cap in accordance with an exemplary embodiment of the present invention;

FIG. 24 shows a blood glucose test strip with a radio frequency identification transponder as part of the test strip in accordance with an exemplary embodiment of the present invention;

FIG. 25 shows a system where the blood glucose monitor receives data from the test strip container and the test strip in accordance with an exemplary embodiment of the present invention;

FIG. 26 is a process flow chart for a parameter-based approach for using therapy times to classify diagnostic test data in accordance with an exemplary embodiment of the present invention;

FIG. 27 is a process flow chart for an analysis-based approach for using therapy times to classify diagnostic test data in accordance with an exemplary embodiment of the present invention;

FIG. 28 is a process flow chart for an analysis-based approach with feedback loop for using therapy times to classify diagnostic test data in accordance with an exemplary embodiment of the present invention;

FIGS. 29, 30 and 31 illustrate the benefits of the connectivity and value added information provided by exemplary embodiments of the present invention in the context of overall patient and disease management;

FIGS. 32, 33, 34, 35, 36 and 37 illustrate current cash flows between DM stakeholders that can be improved by exemplary embodiments of the present invention in the context of overall patient and disease management;

FIGS. 38, 39 and 40 illustrate improvement over current cash flows between DM stakeholders afforded by a pay-for-results model implemented in accordance with an exemplary embodiment of the present invention;

FIGS. 41A, 41B, 41C and 41D each illustrate a blood glucose monitor with a display message in accordance with an exemplary embodiment of the present invention; and

FIGS. 42 and 43 illustrate display screens generated for viewing via a disease management stakeholder computing device in accordance with exemplary embodiments of the present invention.

Throughout the drawings, the same drawing reference numerals will be understood to refer to the same elements, features, and structures.

DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

The matters defined in the description such as a detailed construction and elements are provided to assist in a comprehensive understanding of the embodiments of the invention. Accordingly, those of ordinary skill in the art will recognize that various changes and modifications of the embodiments described herein can be made without departing from the scope and spirit of the invention. Also, descriptions of well-known functions and constructions are omitted for clarity and conciseness.

With regard to the present invention, the term “data” generally refers to numerical values such as blood glucose levels, times of day, dosage amounts, and so on. The term “information” generally refers to educational information, feedback, qualitative status of patient, analysis of data, and so on. DMCs generally have proprietary algorithms for synthesizing information and data received from patients; however, this information and data is often faulty due to inadvertent or intentional misinformation from the patient, poor record keeping, failure to contact patient, and so on.

The present invention provides an improved DM system whereby sharing of patient DM-related data with other stakeholders is fully automated and real-time. Further, improved access to more reliable patient DM data by the other stakeholders allows for improved use of the information to facilitate better management of the disease.

FIG. 2 illustrates the stakeholders in diabetes management. The stakeholders are the patients and optionally their caregivers, their healthcare team members (e.g., physician), their insurers, their employers. As described above, aDMC16 can be hired by a patient's insurer or employer to provide the patient12 with educational support for his or her disease.DMCs16 obtain medical claims data such as prescriptions and visits to healthcare providers, pharmacy data and laboratory data, and then other data such as BG measurements, insulin dosages, A1c levels, diet and exercise. Currently, much of this information is collected from the patient via telephone which is problematic (i.e., expensive, inconvenient and inaccurate). Other stakeholders in DM can be mail order companies providing DM supplies such as test strips to patients and caregivers. As described below, mail order companies currently exist that mail a maximum number of test strips allowed to patients each month by Medicare or other third party payors. This practice of mailing strips leads to unfair billing since many of these strips are unused or used ineffectively. The present invention provides benefits to each of these stakeholders and particularly to disease management companies, healthcare networks and providers, insurers and Centers for Medicare and Medicaid Services (CMSs), whose needs are often not emphasized as technological advances in diabetes management are developed.

FIG. 1 illustrates some of the devices (e.g.,BGM18 and insulin delivery device20) that can be used by a patient12 or his or hercaregiver34 to collect DM-related data and information.FIG. 3 illustrates additional patient devices and some of the stakeholder devices that can be used to connect to arepository50 for diabetes data and information and communicate with patient devices in accordance with an exemplary embodiment of the present invention. The patient devices can include, but are not limited to, BGMs, insulin delivery devices, position tracking devices, nutrition and other data or information input devices. BGMs can be, but are not limited to, non-continuous BGMs (i.e., BGMs that require a patient to draw blood for use as a sample on a test strip that is then inserted into and read by a meter), or continuous monitors (i.e., monitors using a catheter inserted under the skin to take fluid measurements for BG level). Insulin delivery devices can be syringes, insulin pens, insulin jet injectors, external insulin pumps, and implantable insulin pumps. Position tracking devices can be, but are not limited to, pedometers and GPS tracking devices. Other devices for automating DM-related data delivery from the patient12 to other stakeholders can be smart bottles for test strips, and wireless syringes, as described in more detail below. Other examples of patient information can be recording of activities such as diet, exercise and lifestyle (when meals are taken, exercise occurs, etc). A WiMax docking station or cell phone can have a display and be programmed to generate a dialog screen to request input of food intake after a noon-time reading. A GPS tracking device can indicate when patient is at home or the gym and generate a screen to enter exercise information. Similarly, a pedometer can monitor general exercise level via recorded movement.

FIG. 4 illustrates arepository50 in accordance with an exemplary embodiment of the present invention, and types of data and information stored therein. For example, therepository50 can store

data

64 and70 from BGMs and insulin delivery devices,lifestyle information74 such as meal-times and food intake, exercise, patient location, medical data such as cholesterol, blood pressure,information76 pertaining to number of and lot number of test strips allotted to patient, testing frequency and BG level goals and variances, meter/strip calibration data, and so on. Therepository50 also stores for each patientbiographical data60, including one or more recognized patient identifiers as described below, medical data andvital statistics66, physicians orders. Appointment andprescriptions72, among other information. Therepository50 can also containanalytical algorithms78 for analyzing data stored therein and areport generation module80.

With continued reference toFIG. 3, a wireless blood glucose meter (BGM)44 comprising aBGM46 radio frequency (RF)communications circuit48 can communicate with various data users60 (e.g., the patient wireless communication devices such as PDA or laptop or PC, physician and other members of the patient's healthcare team and the disease management company hired to work with patient) via variousRF communications pathways52 in accordance with an exemplary embodiment of the present invention.FIGS. 5-17 illustrate different types of wireless BGMs ordevices44 containing BGMs and their respective communications pathways to the different data and information users. These devices can communicate with the data and information users andrepository50 via acellular network54 and/or the internet directly56 via one ormore devices58 such as a cellular phone, personal data assistant (PDA), docking station, personal computer CPs or other computing device with communications capability. The RF technologies illustrated in these figures include, but are not limited to, cellular, Bluetooth, Wireless USB, WiMax, WiFi and ZigBee.

With reference toFIGS. 5A and 5B, anexemplary wireless BGM44 is shown as constructed in accordance with an illustrative embodiment of the present invention. Thewireless BGM44 includes adisplay84 to show blood glucose level, date and86 time the level was measured, along other information. The wireless BGM has anantenna86, a teststrip reader input88 and an on/offbutton90.FIG. 5B illustrates aport92 for connecting the wireless meter to another device such as a docking station, cellular modem, and so on.

FIG. 6 illustrates components of anexemplary wireless BGM44 as constructed in accordance with an illustrative embodiment of the present invention. Thewireless BGM44 comprises aprocessor96, amemory device98, adisplay108 an input device (e.g., keypad100), atest reader102, acommunications interface circuit104,antenna106 andpower supply110. The test reader can comprise an analogfront end112, that is, a test strip interface between astrip port114 and aprocessor96 for glucose measurement. As described below, a BGM can be provided that operates with a base station, as shown inFIG. 11A, and therefore does not need anantenna106. Acommunications interface circuit104 can be configured to allow thewireless BGM44 to communicate with one or more wireless protocols illustrated inFIG. 4, among others. If thecommunications interface circuit104 enables thewireless BGM44 to communicate via more than one wireless protocol, it can include a scanning device to scan the wireless frequencies available and to select, based on optimal transmission qualities, the best communications protocol to use to transfer data such as the most recent blood glucose reading to the repository.

In accordance with a preferred embodiment of the present invention, thewireless BGM44 requires no user involvement to transmit blood glucose readings following a test to therepository50. For example, the wirelessblood glucose meter44 can be programmed and configured to be an event-driven device that automatically sends recently acquired test data from the reader based on detection of insertion of the strip into the reader, telephone activation if the wireless BGM is built into or connected to a cellular telephone, pressure activation or selected motion activation of the wireless BGM. An embedded acknowledgement function is preferably implemented to ensure that therepository50 received the results completely (i.e., any errors in the transmitted data can be sufficiently corrected or the data is retransmitted).

The wireless connectivity of theblood glucose meter44 to therepository50 and the automated transfer of blood glucose test results via the wireless RF communications pathway facilitate increased compliance of the patient with diabetes management guidelines. This is because the test results are automatically provided to diabetes management stakeholders. Further, the repository data is more comprehensive since the automated delivery of the test results obviates situations where patients or the caregivers fail to test and/or fail to report the test results to the requisite stakeholders. Also, the communication of the data to a repository allows a level of abstraction and analysis of the data to provide other information (e.g., data on the number of tests performed could be used to facilitate test strip prescription tracking and replenishment; data on insulin delivery could be used to facilitate prescription tracking and replenishment of supplies.) In addition, as described above, other disease management information can be transferred to therepository50 and therefore to the requisite stakeholders via the same radio frequency communications pathways such as GPS and pedometer readings, insulin delivery information and meal-time information. These devices can be connected to theblood glucose meter46 and/or itsRF circuit48, or have a separate RF circuit, for communicating this additional information to the repository. Accordingly, unlike present blood glucose readers and communications interfaces such as patients' PCs, data such as blood glucose test results and insulin intake and other disease management information is given a wider view. In other words, the diabetes management data and other information are available to more stakeholders, and the stakeholders have access to more comprehensive information relating to the patient. By contrast, conventional devices generally only give selected test results to selected persons who have only a local view of the test result information and no control over compliance of the patient in testing or reporting the test results. Further, conventional blood glucose meters and other data devices generally use separate communications transactions to send these results to the various persons involved, and generally do not employ a repository for the test results or other information.

In addition, the present invention allows for transfer of information frompatients12 and other stakeholders (e.g.,14,16,40 and42) to the repository and from the repository to patients and to other stakeholders is preferably or ideally in real-time (e.g., immediately following a blood glucose test or insulin injection). It is to be understood, however, that the transfer of data between the stakeholders and therepository50 can be configured to occur within a selected time period following an event (e.g., patient test, or repository algorithmic determination that a patient should receive a selected message), or a selected number of times per day, and so on.

FIG. 4 is a block diagram of anexemplary repository50 in accordance with an exemplary embodiment of the present invention. The repository preferably comprises many records62₁, . . .62_nforrespective patients12 such as data transmitted from wireless meters and syringes or pens, data received via traditional means such being collected as the result of telephone calls between two or more of a physician, disease management representative, insurer, and the patient, information collected from GPS devices, pedometers and meal-time information. As will be described in greater detail below, an illustrative embodiment of the present invention allows for test strip use, lot numbers, calibration data and meter number to be maintained for each patient12. The organization of the data and information and identification of same with respect to aparticular patient12 can be accomplished in a number of different ways. For example, data received from a communications chip configured for use with therepository50 can be sent packetized with a header including a unique identification number assigned to a

device

44 or58 as well as apatient12. Data and information relating to aparticular patient12 can be related to that patient via more than one identification means. For example,wireless meter44 data can use a identification code which can be a randomly generated code, and test strip information can be related to thepatient12 and become a part of the patient's repository records based on a recognized patient ID assigned by Medicare, insurer or other payor, for example.

Returning to the wireless blood glucose meters ofFIGS. 5, 7, 8, 9, 10A and 10B, these devices referred to generally as44 illustrate different RF communication pathways between the wireless blood glucose meter and therepository50.

FIG. 7 illustrates ablood glucose meter44 having a communications circuit configured to communicate with adevice58 such as a PC indicated generally as58avia wireless USB technology. ThePC58a, in turn, can communicate with therepository50 via theinternet56 or acellular network54. In other words, thePC58acan be connected, for example, to theinternet56 via an analog or digital connection or connected to acellular network54 via a cellular modem card.

FIG. 8 illustrates ablood glucose meter44 with thecommunications interface circuit104 having a built-in WiFi or WiMax communications capability for automated data transmission to a router or hub for providing meter data to the repository via the internet.

FIG. 9 illustrates ablood glucose meter44 with thecommunications interface104 circuit having a built-in Bluetooth or ZigBee communications capability for automated data transmission to therepository50 via auser device58csuch as a cell phone, PDA, and the like, via theinternet56 and/or acellular network54.

FIGS. 10A and 10B illustrate ablood glucose meter44 that communicates with therepository50 via acellular network54. As shown inFIG. 10A, theblood glucose meter44 can have a cellular communications chip built into it as thecommunications interface circuit104. Alternatively, the blood glucose meter can be provided with thecellular modem attachment120, as shown inFIG. 10B.

In accordance with the another exemplary embodiment of the present invention, ablood glucose meter44 can be configured for use with adocking station124, as shown inFIGS. 11A, 11B and 11C, in lieu of having acommunications interface circuit104 andantenna106 as described above in connection withFIG. 5A. Thedocking station124 comprises acradle126 for receiving the blood glucose monitor44, adisplay128, and a number of user buttons or controls indicated generally at130. The buttons indicated at130 comprise, but are not limited to, a button for contacting specified persons such as a physician, a button for reviewing reminders sent to the docking station from the repository in accordance with instructions from a disease management representative or physician, a button for displaying menu options on thedisplay128, an emergency button for one-touch dialing of an emergency number such as 911, and a button for indicating quick facts on the display regarding diabetes management. Among the menu options is a send option to send recent blood glucose test results to therepository50 when themeter44 is in thecradle126. With reference withFIGS. 11D and 11E, theportable meter44 has adisplay84, atest strip input88, and on/offbutton90 and aport92 for connecting to a corresponding connector in thecradle126.

With reference toFIG. 11F, thedocking station124 comprises aprogrammable processor132, adisplay128, amemory device134, aconnector136 for electrically communicating with the meter when the meter is inserted in the cradle, a number of buttons and otheruser input devices130, acommunications interface140 to the repository via the internet or a wireless network and apower supply138. Themeter44 has atest strip reader114, aprocessor96, amemory98, adisplay108 and on/offbutton90 or other user input device, and a connector (not shown) for electrically communicating with the docking station when the meter is inserted in the cradle.

As shown inFIGS. 12A and 12B, when theblood glucose meter44 is docked in thedocking station24, the docking station can communicate via wireless technology such as Bluetooth to adevice58 such a cellular phone or PDA which, in turn, communicates with therepository50 via a wireless network or the internet. Alternatively, thedocking station124 can be provided with the cellular modem such that, when themeter44 is in thedocking station cradle124, thedocking station124 can transmit test results to therepository50 via the cellular network.

FIGS. 13-16 illustrate other types of devices having a blood glucose meter and radio frequency connectivity to the repository.

FIGS. 13A, 13B and 13C illustrate acellular telephone142 having a built-intest strip reader144 and display146 similar to that of the blood glucose reader described above in connection withFIGS. 11B and 11C.

As shown inFIG. 14, acellular telephone148 can have automatic data transmission connectivity to thedata repository50 via the cellular network.FIG. 14 illustrates acell phone148 with aBGM attachment150.

FIGS. 15A through 15D are various views of aninsulin delivery device160 such as a syringe that is provided with an RFID tag for transmitting information such as syringe identification number, and data stored in a non-volatile EEPROM in the tag such as insulin-type delivered by the syringe, amount, insulin type, and so on. The amount can be detected and stored based on plunger motion. Accordingly, when aglucose meter44 is proximal to thesyringe160 to create a sufficient electromagnetic field, the RFID in the syringe can be activated to send the data relating to the insulin dose delivered by the syringe.

FIG. 15A is a perspective view of thesyringe160 having acap162 on the needle.FIG. 15B is a perspective view of thesyringe160 having thecap164 at the top of thereservoir166 for the insulin removed. The top of the reservoir can be configured with the RFID tag, the plunger and the plunger motion sensor.FIGS. 15C and 15D are front and side elevated views of asyringe160 having thereservoir cap164 removed.

FIGS. 16A through 16E are various views of anotherinsulin delivery device170, that is, an insulin pen having RF connectivity in accordance with an exemplary embodiment of the present invention.FIGS. 16A and 16B are perspective views of thepen170 with thecap172 on.FIG. 16C is a perspective view of thepen170 with thecap172 removed and the insulin delivery mechanism exposed.FIGS. 16D and 16E are top and side elevated views of the insulin delivery pen with the cap on.

As indicated inFIGS. 16B, 16C and 16D, theinsulin delivery pen170 has adisplay174 for indicating insulin dose and other information such as mix amount, time and date of insulin delivery. Thepen170 is provided with a communication circuit (not shown) for communicating the data to the repository using one of the RF communication pathways described above in connection with theblood glucose meter44.

The exemplary insulin delivery devices shown inFIGS. 15A-15D andFIGS. 16A-16E require no patient or caregiver involvement to communicate the insulin delivery data to the repository. The connected syringe data can be sent when the meter data is sent and basically coincides with blood glucose testing. The connected pen data can be automatically transmitted to therepository50 upon detection of complete insulin delivery. As shown inFIG. 17, the insulin delivery data can therefore be sent using, for example, the wireless transmission methods described above in connection withFIGS. 4 through 10. Other injection devices can include, but are not limited to, microneedle delivery, external and implanted insulin pumps with or without PC interfaces. With further reference toFIG. 17, ameter44 can therefore be configured to communicate with a pump, for example, via a local network and with therepository50 via a wide network. In accordance with the exemplary embodiment of the present invention, thepens170 are configured to store multiple dose information which can be transmitted automatically to the repository.

Exemplary embodiments of the present invention allow for reactive and real-time management of diabetes management data and information by diabetes management stakeholders, in particular stakeholders such as disease management companies, insurers, healthcare networks and employers whose functions have not, in the past, been optimized. As stated above, the automatic transmission of blood glucose meter data and insulin delivery device data to arepository50, and the use of therepository50 to also collect, store and access diabetes management information such as food intake and exercise and other health parameters such as blood pressure and cholesterol, allow for increased patient compliance and more comprehensive information for review by disease management case workers, physicians, insurers, and other diabetes management stakeholders. DMCs, in particular, benefit from the real-time and comprehensive information and data provided to therepository50 in accordance with an exemplary embodiment of the present invention. In the past, problems commonly experienced by disease management companies included lack of real-time data access (i.e., because much of the data was collected via telephone conversations between representative and patients), insufficient physician involvement, inability to scale operations cost-effectively and therefore costly case management. A number of improved disease management operations will now be described with reference toFIGS. 18A and 18B and in accordance with exemplary embodiments of the present invention.

Referring toFIGS. 18A and 18B, disease management companies can now review (block180) the various records available for selected patients in therepository50 and determine when blood glucose test results and other test results such as A1c testing are outside selected parameters for respective patients based on variations in a patient's blood glucose levels and other test results. The disease management company can prioritize which patients need to be contacted by a representative and provided with additional educational information (blocks182 and184). For example, an algorithm at the repository can use parameters specified by a stakeholder to determine those patients whose test results indicate that prompt attention or intervention is needed. A report generating module at therepository50 allows for exception reporting, that is, selection of patients whose parameters meet selected criteria and need an alert message to be sent via the two-way wireless pathway of the present invention, or simply generation of an exception report (blocks208 and210). Thus, a stakeholder can use the reports generating ability of therepository50 to know how many hypoglycemic events occurred among their patients in a given time period. In addition, a disease management company can also improve the assignment of cases among disease management representatives to facilitate their case load management. In addition, variations among a patient's blood glucose data, as well as meal-time habits and other stored information, can be analyzed to allow the data management company to customize the frequency with which a patient tests blood glucose levels and performs other tests such as A1c testing (blocks186 and188). Users can then be sent reminders via the base station or the display on wireless blood glucose meters regarding when to test, if a particular test has been overlooked by the patient, or alerts when levels are outside a selected range (blocks190 and196). Alerts can be custom or generic alerts in accordance with an aspect with the present invention.

With continued reference toFIGS. 18A and 18B, stakeholders can use the repository and two-way radio frequency communications between themselves and patients (i.e., via meters, docking stations, cellular phones, computers, PDAs or other devices) via the communication pathways illustrated inFIG. 4 or other networks such as the public switch telephone network (PSTN). The two-way communications provided by the present invention between the patient and other diabetes management stakeholders allows determining drug therapy compliance (block196) through the analysis ofrepository50 data relating to test strip use verification and insulin doses administered (block198), as well as for the confirmation (block194 and200) of receipt of an alert sent to the patient (e.g., when a test blood has expired or is defective, when test blood glucose levels are outside a selected range, and so on) (blocks192 and206). Therepository50 can comprise different test data such as A1c and glycosylated serum protein test data for analysis by a stakeholder for short-term, mid-term and long-term evaluation of blood glucose levels and prediction of events for a specific patient such as blood glucose levels falling outside a desired range (block202 and204). Therepository50 allows for generation of a greater variety of reports since the data is more comprehensive. For example, disease management companies can perform compliance reporting for selected ones of groups of patients (diabetes patient population trends reports), and real-time exception reporting. Reports can be generated for different stakeholders (e.g., patient, case manager and healthcare provider) that are linked but also have unique portal space in the repository such that notes can be posted and responded to among the stakeholders. Also, reports can be represented differently on the respective stakeholders' computer screens to have varying information and functional features, depending on the stakeholder viewing the report.

Thus, the exemplary embodiment of the present invention provides stakeholders with a means to move from reactive disease management to real-time and proactive disease management and therefore provide such direct benefits as increased productively for case workers and reductions in management cost and time expended, improved clinical outcomes, increased patient care and satisfaction (e.g., due to the real-time aspect of viewing and responding to test data), and greater healthcare team involvement. These benefits lead to such secondary benefits to DMCs as increased patient enrollment and business opportunities. Insurers, for example, can better evaluate financial impact of a disease management program based on outcomes and trends reports that can be obtained from therepository50 described above in accordance with an exemplary embodiment of the present invention, and receive better cost effectiveness from a contracted disease management company. Using one or more of the exemplary embodiments of the present invention described herein, healthcare networks can increase productivity by spending less time gathering data and more time providing care to patients.Repository50 data can be made available to multiple hospital and clinic sites. Patients are more satisfied when healthcare networks enroll in a system in accordance with an exemplary embodiment of the present invention because patient data is available anytime and wherever the patient goes, prescriptions are automated and patient data is securely available to the right people involved with a patient's disease management.

The exemplary embodiment of the present invention also allows disease management companies and other stakeholders to monitor drug therapy compliance. For example, diabetes management stakeholders can review medication dosages reported automatically, as well as collected information in the repository regarding test strip lot and corresponding test results and determine if a patient is maintaining a physician-directed schedule for testing and otherwise managing blood glucose levels. As described above, alerts can be sent when blood glucose levels are outside a selected range or test strips have expired or otherwise need to be replaced. As will be described below in connection withFIG. 19, tracking of test strip use in accordance with an exemplary embodiment of the present invention allows for more effective use of test strips, better control over test strip quality and quantity delivered to patients and more efficient billing to Medicare.

The automated transmission of blood glucose results and test strip lot number and meter calibration data allows for stakeholders with the access to therepository50 to determine those test strips that have actually been used. Currently, Medicare guidelines determine the number of test strips that are sent per month to diabetes patients. Currently, there is no way to track whether the test strips are actually used. Mail order companies are permitted to bill Medicare for the maximum amount of test strips allotted to a patient regardless of whether the test strips go largely unused by the patient. Mail order companies need only contact the patient once each month before sending the Medicare-directed number of test strips to that individual and then billing Medicare for those strips. Accordingly, a significant amount of test strips paid for by Medicare can go unused and without any method of detecting the magnitude of such waste.

With reference toFIG. 19, an exemplary embodiment of the present invention resolves this problem through the automatic transmission of test results from meters (e.g.,

meters

44,142 or148) to therepository50 without any user interaction or interference. Therepository50 can be configured to store the number of test strips allotted by Medicare to a patient, the number of recommended tests per day the patient is to undergo, the number test results that have been received, and determine how many unused test strips a user has within a particular month (blocks222 and240). Based on this information, it can be determined whether a user needs a refill of test strips. Billing can therefore be on the basis of number of test strips that have actually been used, representing a significant savings to Medicare and other payors over current wasteful practices. Therepository50 and the automated communications described herein in accordance with exemplary embodiments of the present invention also allow for determination of refills and automated fulfillment of same since the number of unused test strips that are left can be determined (blocks226 and228). A vendor can use these automated communications and therepository50 to estimate when a patient is going to be out of test strips and can automatically send more when the patient has only, for example, a two week supply left Alternatively, a vendor can be sent a message to send no more refills until a prescribed number of test results are received (block240).

With continued reference toFIG. 19, therepository50 also allows for review of testing practices and blood glucose results and can send promotional material from pharmacies or pharmaceutical companies to selected patients. As described above, the connected blood glucose meter (e.g., anRF meter44 or acell phone meter142 or148) provides for ability to send not only messages from the patient's healthcare team, or educational content to the patient, but also other types of messages. For example, as part of a business model in accordance with an exemplary embodiment of the present invention, advertising can be sold to companies who have targeted messages that they want these patients to receive (blocks230 and232). For illustrative purposes, a pharmaceutical company that is introducing a new diabetes therapy can therefore buy an advertisement that is transmitted to those patients whose health profile fits a potential target for the new therapy. These profiles can be obtained using algorithms and report generation operations of therepository50.

In addition, as indicated inFIG. 19, overall accuracy of test strips and meters can be monitored by reviewing blood glucose levels, test trip lot numbers and meter calibration information (block238). Finally, if test results are consistently outside desired parameters or nonexistent, alerts can be sent in the event that the test strips are defective or the

meter

44,142 or148 is malfunctioning (

blocks

234,236 and238). Accordingly, vendors can be advised to send replacement strips for malfunctioning or expired tests strips. Thus, automated test results reporting and management of other data such as test strip lot numbers and patient data such as recommended frequency of testing and therefore test strip usage tracking presents many advantages over current diabetes management systems such as tracking of expired or defective test strips, eliminating abusive practices such as test strip hoarding and unfair billing to Medicare or Medicaid, and monitoring associations between test strips and meters, to name a few.

Currently, Medicare requires mail order companies to call and ask patients if they need more test strips before sending them. Mail order companies can avoid the time and expense of making such calls since the number of test strips actually used can be tracked using the connectivity and repository of the present invention. Further, DMCs find the hiring of staff nurses to manage case loads to be difficult and expensive. The device connectivity andrepository50 described herein in accordance with exemplary embodiments of the present invention, however, can provide patients with a virtual coach and reduce reliance on nurses and other case managers. Using algorithms at the

patient device

44,142 or148 or in therepository50, the collected and stored data and information at therepository50 and the two-way communication function described herein, points of education can be generated and sent via message to the patient as needed to improve medical outcomes.

The exemplary embodiments of the present invention also allow for different and advantageous programs to be implemented. For example, with reference toFIG. 20, a cellular network-based system can be implemented wherein a monthly subscription fee can be determined based on test frequency and the number of times test data is uploaded to the repository (block250). Once monthly subscribers are enrolled, they can be provided with blood glucose meters and test strips at no cost or at nominal cost, obviating the above-mentioned abusive practices of billing Medicare for unused strips (block252). As the test data for a particular subscriber is uploaded, it can be reviewed to determine if more strips are needed (

blocks

254,256,258 and260). Also, patients' overall ability to manage the blood glucose within desired ranges can be determined and cash-back incentives or other promotional items can be provided to physicians and/or patients exhibiting improved diabetes management through their improved comprehensive test results (blocks262 and264). In addition, the third party payor (e.g., Medicare) would only pay for those test strips that had an associated result in thedata repository50 thereby reducing the likelihood of fraud and abuse in the system of reimbursement for diabetes supplies.

In accordance with an aspect of the present invention, radio frequency identification (RFid) technology is employed to realize advantages over existing disease management devices. The term “radio frequency identification transponder” is used to refer to any of a class of compact radio receiver-transmitters that are powered by an ambient radio frequency field. The transponder is accessed by modulating the field with an appropriate communication signal. The reaction can be a responsive signal, a change in the transponder, or both. The content of the communication signal and the response of the transponder are limited by the memory and control functions provided by the transponder and by the access time bandwidth available for communication. Within those limits, the transponder can be read and written in a manner similar to other digital memory devices used to store and retrieve digital information. Radio frequency identification transponders are widely available in a variety of forms. These devices include a non-volatile memory, such as an Electrically Erasable Programmable Read-Only Memory (EEPROM) semiconductor component integrally contained in the transponder. Stored in the nonvolatile memory are encoded data. The radio frequency identification transponder also contains an antenna. The shape of the transponder and the antenna can vary depending on the specific embodiment. Memory and any control functions are provided by chip mounted on the support and operatively connected through the leads to the antenna.

In accordance with an exemplary embodiment of the present invention, a blood glucose monitor270 is provided which has abody272, a glucose sensor (not shown) mounted in the body, adisplay274, a radiofrequency identification transceiver276, and at least one radiofrequency identification transponder278 mounted within the body, as shown inFIGS. 21A and 21B. Thetransceiver276 andtransponder278 are unshielded by the body. Thelines290 represent an ambient-frequency field generated by thetransceiver276.

During use, acontainer280 of test strips including a radio frequency identification transponder282 (e.g., integrated into acontainer label284 or thelid286 as shown inFIGS. 22 and 23, respectively) orindividual test strips288 containing a radio frequency identification transponder (FIG. 24) have their radiofrequency identification transponders282 activated by the blood glucose monitor'stransceiver276, as indicated by theline pattern290 inFIG. 25. This results in thecontainer280 of test strips, or theindividual test strip288, transmitting data comprising an encodement (indicated by line pattern292) necessary for themonitor270 to calculate an accurate measure of the blood glucose level in the blood sample applied to thetest strip288.

This exemplary embodiment of the present invention realizes a number of advantages and improvements over the existing diabetes management devices. The typical use of a conventional blood glucose monitor requires that the user manually enter a code number into the blood glucose monitor that corresponds to the code number printed by the manufacturer on the test strip container. This code number is a type of calibration data that ensures that the results obtained are accurate to the degree claimed by the manufacturer in the labeling for the test strips. If the user of the blood glucose monitor does not pay attention to this code number or enters an incorrect code number, the blood glucose results obtained could be significantly different than the results obtained with a correct code number. A significantly higher or lower result could lead to incorrect medical therapy by the user or the healthcare professional performing the blood glucose test. By contrast, having theencodement292 transmitted from the test strip container or the individual test strip in accordance with the exemplary embodiment of the present invention ensures that the blood glucose test provides the most accurate result, eliminating the likelihood of an inaccurate result due to user error. Also, the encodement can contain additional information such as, for example, date of manufacture, the test strip expiration date, lot number, manufacturer identification, and logistic information such as distribution country or region. This additional information can be stored in therepository50 and used by the system of the present invention, which is exemplified by the illustrative embodiments disclosed herein, to provide alerts or warnings about the expiration date, to enable or disable use of certain combinations of meters and test strips depending on the country or region, and to aid logistics management.

The present invention, which is exemplified by the illustrative embodiments disclosed herein, provides solutions to prior art problems. When the blood glucose test strips are manufactured and a calibration code is established for a particular lot, this code is embedded in the radiofrequency identification transponder282 of either thecontainer280 holding these test strips, theindividual test strips288, or both. When acontainer280 of test strips or anindividual test strip288 is in close proximity to the blood glucose monitor270, the blood glucose monitor'stransceiver276 creates afield290 that activates the container or test strip radiofrequency identification transponder282 which then automatically transmits its embeddedcode292 to theblood glucose monitor270. The blood glucose monitor270 then uses this code in calculating the blood glucose result that is displayed once a test strip with a blood sample has been received in the blood glucose monitor. Further, theencodements292 can include information about the individual test, whether from the transponder in the container, the transponder in the test strip, or the transponder contained within the monitor itself. Examples will now be described.

In a first example, two elements contain radio frequency identification transponders, that is, the blood glucose monitor270 and thetest strip container280. In this example, the close proximity of the test strip container to the blood glucose monitor is required for the monitor to receive the calibration code.

In a second example, two elements contain radio frequency identification transponders, that is, the blood glucose monitor272 and the individual test strips288. In this example, the close proximity of the test strip due to its insertion in the blood glucose monitor is required for the monitor to receive the calibration code.

In a third example, three elements contain radio frequency identification transponders, that is, the blood glucose monitor270, thetest strip container280, and the individual test strips288. In this example, the close proximity of both the test strip container and the individual test strip are used as a confirmation by the blood glucose monitor that the inserted test strip has the same calibration code as that transmitted by the test strip container.

In a fourth example, thetest strip container280 stores and transmits the calibration code, the test strip expiration date, and the lot number. These data are interpreted by themeter270 by comparing the test strip expiration date to the current date set in the meter to determine if thetest strip288 being used has expired or not.

In a fifth example, thetest strip288 stores and transmits the calibration code, the test strip expiration date, and the lot number. These data are interpreted by themeter270 by comparing the test strip expiration date to the current date set in the meter to determine if the test strip being used has expired or not.

In a sixth example, the radiofrequency identification transponder278 in the blood glucose monitor270 is used for communication with other devices such as a pump or docking station or detector in warehouse or manufacturing location. In other words, a pump or docking station can transmit a field via a transceiver to determine if aBGM270 is listening and can communicate with it. A detector can transmit a field that activates the radio frequency identification transponders of the blood glucose monitors packed in a crate to determine if any of them were incorrectly packed and therefore to avoid shipping errors.

In accordance with an exemplary embodiment of the present invention, a means for automatically determining the association of a diagnostic test performed by an individual to a mealtime is provided. The association of a diagnostic test to a mealtime is based on the timing of a therapeutic intervention performed by the individual. The present invention is directed to both an analytical process and the parameters used by the analytical process. The present invention is exemplified when determining, for a given blood glucose test, whether that test is taken prior to a meal or after a meal based on the timing of an associated insulin injection. Described below are two methods, that is a parameter-based method (FIG. 26) and an analytical method (FIG. 27), for automatically making this determination in accordance with exemplary embodiments of the present invention.

In the parameter-based method (FIG. 26), the determination relies on therapy data (e.g., insulin injections) as indicated byblock300 and diagnostic test data (e.g., blood glucose meter test results) as indicated byblock302 and their corresponding time stamps, as well as a set of parameters (block304) provided by the individual as follows:

- A single time representing the latest an individual would eat their first meal (M1);
- A single time representing the latest an individual would eat their second meal (M2);
- A single time representing the latest. an individual would eat their third meal (M3);
- A single time representing the latest an individual would go to sleep (S1); and
- A single time representing the latest an individual would test their blood glucose in the middle of the night. (N1).

In the parameter-based method, the determination also relies on a set of timing thresholds internal to the analysis as follows:

- blood glucose test times that are less than or equal to 30 minutes before the injection time are categorized as before the meal (blocks310 and312);
- blood glucose test times that are greater than or equal to 90 minutes AND less than or equal to 180 minutes after the injection time are categorized as after the meal (blocks314 and320);
- blood glucose test times that are less than or equal to 45 minutes before the injection time AND are greater than or equal to 180 minutes after the previous injection time are categorized as before the meal (blocks312 and318); and
- blood glucose test times that are greater than or equal to 30 minutes after the injection time AND are less than or equal to 90 minutes after the injection time are categorized as unknown (blocks316 and322).

The allocation of values (block308) in accordance with this exemplary embodiment of the present invention is as follows:

- if the injection time is before M1 on a given day, that injection will be associated with the first meal of the day;
- if the injection time is after M1 and before M2 on a given day, that injection will be associated with the second meal of the day;
- if the injection time is after M2 and before M3 on a given day, that injection will be associated with the third meal of the day;
- if the injection time is after M3 and before S1 on a given day, that injection will be associated with the bedtime for that day; and
- if no injection time and the blood glucose test time is after N1 and before N1+5 on a given day, that blood glucose test will be associated with a nighttime test.

Contention between multiple tests is resolved in accordance with this exemplary embodiment of the present invention as follows: if two blood glucose tests are performed prior to an insulin injection, the blood glucose test closest in time to the injection time is used for the analysis. Based on these parameters, a data set of insulin injection times and blood glucose test times can be analyzed to determine the following, for example:

- which blood glucose tests are associated with an injection; and
- whether the blood glucose test is categorized as a before meal test or an after meal test for three mealtimes, a bedtime test, or a nighttime test.

In the analysis-based method (FIG. 27), the determination relies on performing an analysis of the individual's data to determine:

- the number of injections for each day; and
- the number of blood glucose tests for each day (block330).
  Additionally, the individual can provide a number representing the typical number of meals eaten per day (block332).

Insulin injection times and blood glucose test times are examined to determine how the times cluster (block334). This may be performed using average times and some measure of variation and confidence intervals around those times throughout the day, relative to the number of meals eaten per day (block336). This provides a means to segment the day into mealtimes, bedtime, and nighttime. Once the values are segmented, the analysis proceeds as in the parameter-based method described above to determine whether a blood glucose test is before a meal or after a meal using the timing thresholds, that is:

- blood glucose test times that are less than or equal to 30 minutes before the injection time are categorized as before the meal (blocks310 and318);
- blood glucose test times that are greater than or equal to 90 minutes AND less than or equal to 180 minutes after the injection time are categorized as after the meal (blocks314 and320);
- blood glucose test times that are less than or equal to 45 minutes before the injection time AND are greater than or equal to 180 minutes after the previous injection time are categorized as before the meal (blocks312 and318); and
- blood glucose test times that are greater than or equal to 30 minutes after the injection time AND are less than or equal to 90 minutes after the injection time are categorized as unknown (blocks316 and322).

This aspect of the present invention realizes a number of advantages and improvements over the prior art. In the past, the determination of mealtimes was wholly dependent on one of two conventional methods:

1. An individual assigning fixed times to their before and after meal time periods; and

2. An individual “marking” their data in such a way as to indicate whether a test or action occurred before or after a meal, at bedtime, or in the night. In the first conventional method, a problem occurs in that the fixed times cannot take into account variations in daily life that might change the timing of meals, bedtime, or a middle of the night event. As a result, data that are from a time period after a meal are misrepresented as having occurred before a meal and vice versa. In the conventional second method, a burden is placed on the individual to make an extra effort to categorize each event either for later analysis or retrospectively “marking” each value according to its category. It is unlikely that an individual will either spend the time to mark every event, or that they will remember to mark every event at the time it occurs. Further, if they perform the “marking” retrospectively, the accuracy of their recollection is diminished, thus diminishing the accuracy of the event allocation.

The exemplary embodiments of the present invention described in connection withFIGS. 26 and 27 solve problems encountered with these conventional methods. First, these embodiments use the timing of a therapy intervention that is typically associated with the period immediately before a meal or immediately before bedtime and uses its occurrence as a proxy for the mealtime or bedtime. Thus, the accuracy of these embodiments of the present invention are directly related to the accuracy of the time information for the therapy intervention. Accordingly, if the therapy intervention's timestamp is itself automated and more accurately determined, the manner by which these embodiments correctly categorize the diagnostic test's timing is improved. Secondly, these embodiments establish timing thresholds that provide the ability to determine the most likely physiologic relationship between the therapy intervention and the diagnostic test.

With reference toFIG. 28, a variation of the analysis-based embodiment described above is used with an analytic engine that contains an iterative learning algorithm that uses feedback from the individual to improve the accuracy of the categorizations over time. That is, with the initial dataset from an individual, the analytic engine can perform as described above, but the individual can then provide feedback in the form of corrections or changes to the categories defined by the engine (block340). The analytic engine then incorporates this feedback into its algorithm and, on successive analyses, requires fewer corrections (block342).

The underlying technical principle of this aspect of the present invention is a series of date and time comparisons that are performed on a dataset comprising two categories of values, where each value in each category has a unique date and time stamp. The first part of the approach compares the dates and times of the two categories of data to find close associations in time between data points. The second part of the approach is dependent on whether a parameter-based method (FIG. 26) is used or an analysis-based method (FIG. 27) is used. In general though, this part makes the assignment to categories of before or after meal, bedtime, or nighttime according to external parameters or to a statistical analysis of the dataset.

Fundamental to both methods ofFIGS. 26 and 27 is the ability to establish timing thresholds that link the two categories of data or values. These timing thresholds would be based on clinical experience and physiologic data, or based on an analysis of an individual dataset over time. A related aspect of the present invention is the improvement in accuracy as the therapy intervention's date and timestamp accuracy improves, particularly if the therapy intervention's date and timestamp is automatically determined and stored in the dataset. The dataset (e.g., the two categories of data, and their associations in time), and the algorithm(s) for implementing the parameter-based or analysis-based methods, can be provided in repository or within the devices themselves. Placing the dataset and algorithm(s) in therepository50 simplifies the device and realizes the advantages discussed above (e.g., reduced development time and therefore time to market, reduced complexity and therefore reduced potential for safety hazards, increased useable life of the device). In any event, the data in therepository50 or within the devices themselves (e.g., meter44) can be analyzed to abstract information about the patient's behaviors. This analysis can realize another advantage of improved messaging. In other words, therepository50 can perform one or more algorithms to determine when messages such as alerts and educational messages should be sent to patients. A patient's test results, insulin intake and mealtimes can be analyzed to determine an optimal time at which to send a reminder message to the patient to take a test or administer insulin or schedule a physician's office visit, for example. Also, algorithmic processing of therepository50 contents can affect the determination of a patient's readiness and willingness to receive information to that will optimally impact a change in that patient's behavior and his or her diabetes management practices.

Another benefit is that with a device (e.g., meter44) that has an “always on” wireless connection, sophisticated firmware in the devices is no longer needed for performing analytical operations. For example, many BGM devices today provide BG averages, or graphical trend data, and so on. With the kinds of systems described herein in accordance with exemplary embodiments of the present invention, the devices (e.g.,

meters

44,142 and148) need not have any of these analytical capabilities, but rather merely act as display devices for the analytics performed at the repository level. In this way, the devices become less complex, which provides a number of benefits (e.g., reduced development time and therefore time to market; reduced complexity and therefore reduced potential for safety hazards, increased useable life of the device because software “upgrades” are performed at the repository level, not at the device level so devices do not have to be replaced, the ability to perform device firmware upgrades wirelessly without requiring the device to be replaced.

FIGS. 29-31 describe improved services and potential revenue benefits realized by the system of the present invention depicted inFIGS. 3 and 4 and described herein as exemplified inFIGS. 5athrough17.FIGS. 29, 30 and 31 illustrate the benefits of the connectivity and value added information provided by exemplary embodiments of the present invention in the context of overall patient and disease management.

As shown inFIG. 29, the left side of hashed line demarcates current measurement practices of different diagnostic data that is shared between a patient, a healthcare provider and other parties as described above in the background section. The right side of hashed line indicates advantages of the exemplary embodiments of the present invention. For example, the effortless data capture and send operations of the connected BGMs, continuous glucose monitors (CGMs) and insulin delivery devices and the “information from data” services provided using therepository50, as described herein in accordance with exemplary embodiments of the present invention, provide integrated services for both customers and businesses including, but not limited to, patients, caregivers, DMCs, healthcare providers, integrated health networks (IHNs), employers and insurance companies. In addition to diabetes, the patient management and disease management services provided by the exemplary embodiments of the present invention are useful for different types of healthcare conditions including, but not limited to, pulmonary care, cardiac care, fitness/well-being care. Examples are provided inFIGS. 30 and 31 such as a diabetes nurse educator (DNE) tracking hundreds of patients through a repository portal and noting that certain patients need immediate attention.

FIGS. 32-37 illustrate retail money flow advantages provided by exemplary embodiments of the present invention. For example,FIGS. 32 and 33 each illustrate product flow such as test strips from a BGM manufacturer to a patient via a wholesaler and retailer, and revenue flow between these parties.FIGS. 35 and 36 illustrate similar parties except for a third party payer such as a managed care organization in lieu of Medicare.FIG. 37 also includes a pharmacy benefits manager (PBM).FIG. 34 illustrates product flow from a BGM manufacturer to a patient via a durable medical equipment supplier or DME, and revenue flow between these parties. The accurate test result reporting, proactive disease counseling, test strip tracking and other advantages of the exemplary embodiments of the present invention provide the additional benefit of significant cost savings and therefore can allow for rebates as shown.

FIGS. 38, 39 and 40 illustrate improvement over current cash flows between DM stakeholders afforded by a pay-for-results model implemented in accordance with an exemplary embodiment of the present invention such as determining actual use of test strips. As shown inFIG. 38, a disease management company can determine from an order in therepository50 that a patient should receive 50 test strips per month based on their current prescribed testing frequency. A mail order or retail vendor can purchase 50 strips from a BGM manufacturer and ship them to the patient and bill the DMC. The DMC and/or payor can, in turn, determine from the repository that only 46 test strips were used by the patient during a selected period of time as determined using the method described above in accordance an exemplary embodiment of the present invention. The payor need only pay for 46 test strips. The DMC and/or payor can receive a rebate for the4 unused test strips.

FIGS. 41A through 41D, 42 and 43 illustrate additional advantages of the connected disease management devices and data capture and analyses methods described herein with reference to exemplary embodiments of the present invention.FIG. 41D illustrates how the system illustrated inFIG. 3 collects data such as blood glucose level, date and time, among other optional data such as pre-meal and post-meal readings. As shown inFIG. 41B, a user is given real-time feedback based on information analyzed in the repository50 (e.g., ADA target or physician prescribed target values for blood glucose levels). As shown inFIG. 41C, the data in the repository can be used to calculate a required insulin dose or other medication that can be transmitted to the BGM to prompt users to take required medication level. With reference toFIG. 41D, the testing and dosage data, among other information such as nutrition and pre-meal or post-meal blood glucose levels, is stored in therepository50 for use by various stakeholders such as a patient, healthcare provider, DMC and so on. As shown inFIG. 42, the data can be collected, analyzed and summarized in a display screen for a number of patients to more effectively manage diabetes patient populations. The display screen can include recent readings, averages over a selected number of days and insulin dose compliance that is color coded or shaded to enhance identification of patients whose ranges or readings are high, low or within a target range. As show inFIG. 43, the data for a selected patient can be captured on a display screen as a one-page action plan with additional information such as blood glucose averages over time.

It is to be understood that the exemplary embodiments of the present invention described herein can be embodied as computer-readable codes on a computer-readable recording medium. The computer-readable recording medium is any data storage device that can store data which can thereafter be read by a computer system. Examples of the computer-readable recording medium include, but are not limited to, read-only memory (ROM), random-access memory (RAM), CD-ROMs, magnetic tapes, floppy disks, optical data storage devices, and carrier waves (such as data transmission through the Internet via wired or wireless transmission paths). The computer-readable recording medium can also be distributed over network-coupled computer systems so that the computer-readable code is stored and executed in a distributed fashion. Also, functional programs, codes, and code segments for accomplishing the present invention can be easily construed as within the scope of the invention by programmers skilled in the art to which the present invention pertains.

While certain exemplary embodiments of the invention have been shown and described herein with reference to certain preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims and their equivalents.